{
  "id": 3297484,
  "title": "Evolocumab and Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis",
  "url": "https://urgent.news/2026/08/25/evolocumab-and-cardiovascular-events-in-patients-with-diabetes-3297484",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-25T00:00:00.000Z",
  "source": {
    "name": "JAMA",
    "slug": "jama",
    "url": "https://jamanetwork.com/journals/jama/fullarticle/2852003"
  },
  "original_language": "en",
  "account": null,
  "summary": "To the Editor In the VESALIUS-CV trial, Dr Marston and colleagues reported that evolocumab reduced first major adverse cardiovascular events (MACE) in patients with diabetes taking optimized lipid-lowering therapy and without known significant atherosclerosis over 5 years of follow-up. While the results are reassuring, additional context regarding absolute benefit and economic considerations may…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "JAMA",
        "title": "Evolocumab and Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis",
        "url": "https://urgent.news/2026/08/25/evolocumab-and-cardiovascular-events-in-patients-with-diabetes",
        "published": "2026-08-25T00:00:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}